Publications
Detailed Information
Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jeong Hun | - |
dc.contributor.author | Kim, Jin Hyoung | - |
dc.contributor.author | Yu, Young Suk | - |
dc.contributor.author | Cho, Chang Sik | - |
dc.contributor.author | Kim, Kyu-Won | - |
dc.date.accessioned | 2012-07-02T00:26:22Z | - |
dc.date.available | 2012-07-02T00:26:22Z | - |
dc.date.issued | 2009-03 | - |
dc.identifier.citation | JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM; Vol.29 3; 621-628 | ko_KR |
dc.identifier.issn | 0271-678X | - |
dc.identifier.uri | https://hdl.handle.net/10371/78019 | - |
dc.description.abstract | Diabetic retinopathy (DR) is the leading cause of vision loss as a major complication of diabetes mellitus. The blood-retinal barrier (BRB) breakdown is a critical early event in the pathogenesis of DR. It has been known that the rennin-angiotensin system (RAS) is important in the progression of the DR via angiotensin II (Ang II), the effector of RAS. In this study, we showed that blockade of Ang II attenuates vascular endothelial growth factor (VEGF)-mediated BRB breakdown in DR. In streptozotocin-induced diabetes, retinal vascular permeability increased with upregulation of VEGF, where Ang II and its receptors were upregulated. Ang II induced VEGF expression in retinal endothelial cells accompanied by loss of tight junction proteins. However, the blockade of Ang II by perindopril, an angiotensin converting enzyme (ACE) inhibitor, inhibited upregulation of VEGF, and prevented the loss of tight junction proteins. Moreover, inhibition of Ang II by perindopril attenuated increased vascular permeability of diabetic retina accompanied by recovery of tight junction proteins in retinal vessels. Therefore, we suggest that the RAS involves in increased vascular permeability during early stage of DR, which is mediated by VEGF. Furthermore, the ACE inhibitor may have a therapeutic potential in the treatment of diabetic BRB breakdown. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | NATURE PUBLISHING GROUP | ko_KR |
dc.subject | angiotensin II | ko_KR |
dc.subject | Tight junction | ko_KR |
dc.subject | VEGF | ko_KR |
dc.subject | diabetic retinopathy | ko_KR |
dc.subject | angiotensin converting enzyme inhibitor | ko_KR |
dc.subject | blood-retinal barrier | ko_KR |
dc.title | Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김정훈 | - |
dc.contributor.AlternativeAuthor | 김진형 | - |
dc.contributor.AlternativeAuthor | 유영석 | - |
dc.contributor.AlternativeAuthor | 조창식 | - |
dc.contributor.AlternativeAuthor | 김규원 | - |
dc.identifier.doi | 10.1038/jcbfm.2008.154 | - |
dc.citation.journaltitle | JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM | - |
dc.description.citedreference | KIM JH, 2008, J NEUROSCI RES | - |
dc.description.citedreference | Kim JH, 2007, BRIT J OPHTHALMOL, V91, P1541, DOI 10.1136/bjo.2007.115220 | - |
dc.description.citedreference | Davidson JA, 2007, ENDOCRINE, V32, P107, DOI 10.1007/s12020-007-0040-9 | - |
dc.description.citedreference | Choi YK, 2007, J NEUROSCI, V27, P4472, DOI 10.1523/JNEUROSCI.5368-06.2007 | - |
dc.description.citedreference | Kim JH, 2007, CURR EYE RES, V32, P693, DOI 10.1080/02713680701487871 | - |
dc.description.citedreference | Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339 | - |
dc.description.citedreference | Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987 | - |
dc.description.citedreference | Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P2925, DOI 10.1167/iovs.04-1476 | - |
dc.description.citedreference | Min JK, 2005, CIRC RES, V96, P300, DOI 10.1161/01.RES.0000155330.07887.EE | - |
dc.description.citedreference | Ebrahimian TG, 2005, ARTERIOSCL THROM VAS, V25, P65, DOI 10.1161/01.ATV.0000149377.90852.d8 | - |
dc.description.citedreference | Frank RN, 2004, NEW ENGL J MED, V350, P48 | - |
dc.description.citedreference | Sarlos S, 2003, AM J PATHOL, V163, P879 | - |
dc.description.citedreference | Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889 | - |
dc.description.citedreference | Tamarat R, 2002, LAB INVEST, V82, P747, DOI 10.1097/01.LAB.0000017372.76297.EB | - |
dc.description.citedreference | Yoshiji H, 2002, ANTI-CANCER DRUG, V13, P221 | - |
dc.description.citedreference | Silvestre JS, 2001, CIRC RES, V89, P678 | - |
dc.description.citedreference | Lorenzi M, 2001, DIABETOLOGIA, V44, P791 | - |
dc.description.citedreference | Fujii T, 2001, IAWA J, V22, P1 | - |
dc.description.citedreference | Moravski CJ, 2000, HYPERTENSION, V36, P1099 | - |
dc.description.citedreference | de Gasparo M, 2000, PHARMACOL REV, V52, P415 | - |
dc.description.citedreference | Fabre JE, 1999, CIRCULATION, V99, P3043 | - |
dc.description.citedreference | ANTONETTI DA, 1999, SEMIN OPHTHALMOL, V14, P240 | - |
dc.description.citedreference | Otani A, 1998, CIRC RES, V82, P619 | - |
dc.description.citedreference | Chaturvedi N, 1998, LANCET, V351, P28 | - |
dc.description.citedreference | Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820 | - |
dc.description.citedreference | Volpert OV, 1996, J CLIN INVEST, V98, P671 | - |
dc.description.citedreference | Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159 | - |
dc.description.citedreference | AIELLO LP, 1994, NEW ENGL J MED, V331, P1480 | - |
dc.description.citedreference | VANDYK DJ, 1994, EUR J CLIN INVEST, V24, P463 | - |
dc.description.citedreference | SATO T, 1993, CELL MOL NEUROBIOL, V13, P233 | - |
dc.description.citedreference | DANSER AHJ, 1989, J CLIN ENDOCR METAB, V68, P160 | - |
dc.description.citedreference | CUNHAVAZ JG, 1979, DIABETES, V28, P16 | - |
dc.description.tc | 17 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.